An update from Celcuity ( (CELC) ) is now available.

Among last week’s news, US biotech Celcuity leapt 180% on new Phase III data for its cancer drug candidate gedatolisib. US drugmaker Madrigal Pharmaceuticals entered into a licensing deal with China’s ...

Celcuity ( (CELC)) has issued an announcement. On July 30, 2025, Celcuity Inc. entered into an underwriting agreement with several underwriters to issue and sell $175 million in Convertible Senior ...

Key earnings this week will include PLTR, ON, AMD, CAT, & PFE. With Trump's revised tariff orders, investors will be keeping an eye on economic reports releasing next week.